Paris-The International Consultation on Prostate Cancer recommends thatmen with a history of prostate cancer not be given testosterone supplementationunder any circumstance. The recommendation was the subject of lively debateat the consultation's 2002 meeting here, and some members of the audienceposed cases in which they thought hormone replacement might be appropriate.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.